Alignment Healthcare’s chief expertise officer sells $217,276 in inventory

Hakan Kardes, the Chief Expertise Officer of Alignment Healthcare, Inc. (NASDAQ:ALHC), a healthcare firm with a market capitalization of $2.87 billion that has seen its inventory surge 122% over the previous yr, has lately bought 14,500 shares of the corporate’s frequent inventory. The shares have been bought at a weighted-average value of $14.9846, leading to a complete transaction worth of $217,276. Following this sale, Kardes retains possession of 295,444 shares. In accordance with InvestingPro evaluation, the inventory is presently buying and selling close to its 52-week excessive of $15.05.

The transaction was performed beneath a pre-established Rule 10b5-1 buying and selling plan, adopted on March 14, 2024. The shares have been bought in a number of transactions at costs starting from $14.98 to $15.00 per share. InvestingPro knowledge signifies the inventory is presently in overbought territory, with 11 further key insights obtainable to subscribers.

In different latest information, Alignment Healthcare has seen a collection of constructive developments. Stifel analysts have raised the corporate’s value goal from $14.00 to $16.00, sustaining a Purchase ranking and highlighting Alignment’s strong Annual Enrollment Interval outcomes. This follows the corporate’s spectacular 43.5% income progress during the last twelve months and a 35% year-on-year improve in well being plan membership, reaching roughly 209,900 members. Anticipated membership progress is predicted to succeed in between 225,000 and 231,000 by the tip of 2025.

Moreover, the corporate’s third-quarter outcomes for 2024 displayed a 58% improve in well being plan membership and a 52% improve in whole income, amounting to $692 million. TD Cowen, a monetary providers agency, responded to those robust outcomes by elevating its value goal for Alignment Healthcare from $10.00 to $13.00, whereas sustaining a Purchase ranking. The corporate’s administration can also be anticipating at the least a 20% progress in Medicare Benefit membership and an adjusted EBITDA of over $40 million by 2025.

These latest developments point out a constructive outlook for Alignment Healthcare, with analysts from Stifel and TD Cowen expressing confidence within the firm’s strategic positioning and progress potential.

This text was generated with the assist of AI and reviewed by an editor. For extra data see our T&C.